Tags

Type your tag names separated by a space and hit enter

Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease.
Curr Opin Clin Nutr Metab Care 2010; 13(5):569-73CO

Abstract

PURPOSE OF REVIEW

Inflammatory bowel disease (IBD) is a debilitating and widespread immune-mediated illness of unknown etiology. Current treatments are modestly successful and with significant side-effects. The purpose of this review is to summarize the current understanding of mechanisms of action underlying the anti-inflammatory actions of conjugated linoleic acid (CLA) and n-3 polyunsaturated fatty acids (PUFAs) in IBD.

RECENT FINDINGS

Nutrition-based interventions that target peroxisome proliferator-activated receptors (PPARs) such as dietary CLA and n-3 PUFA have demonstrated anti-inflammatory efficacy in animal models of IBD. Clinical data on n-3 PUFA in IBD remains generally unimpressive, although results of a recent human study demonstrate that IBD remission can be maintained by maintaining the n-3: n-6 ratio more than 0.65 via n-3 PUFA intervention. In mice, CLA prevented inflammation-driven colorectal cancer by activating PPAR gamma and modulating regulatory T cells and macrophages. CLA is the subject of an ongoing clinical study in Crohn's disease patients.

SUMMARY

Compelling evidence demonstrates that n-3 PUFA and CLA prevent or ameliorate IBD in animal models. However, this basic knowledge has not been translated into novel nutrition-based clinical interventions. For both compounds there is an urgent need for placebo-controlled, large-scale, multicenter clinical trials.

Authors+Show Affiliations

Laboratory of Nutritional Immunology and Molecular Nutrition, Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA. jbassaga@vt.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20508519

Citation

Bassaganya-Riera, Josep, and Raquel Hontecillas. "Dietary Conjugated Linoleic Acid and N-3 Polyunsaturated Fatty Acids in Inflammatory Bowel Disease." Current Opinion in Clinical Nutrition and Metabolic Care, vol. 13, no. 5, 2010, pp. 569-73.
Bassaganya-Riera J, Hontecillas R. Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2010;13(5):569-73.
Bassaganya-Riera, J., & Hontecillas, R. (2010). Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Current Opinion in Clinical Nutrition and Metabolic Care, 13(5), pp. 569-73. doi:10.1097/MCO.0b013e32833b648e.
Bassaganya-Riera J, Hontecillas R. Dietary Conjugated Linoleic Acid and N-3 Polyunsaturated Fatty Acids in Inflammatory Bowel Disease. Curr Opin Clin Nutr Metab Care. 2010;13(5):569-73. PubMed PMID: 20508519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. AU - Bassaganya-Riera,Josep, AU - Hontecillas,Raquel, PY - 2010/5/29/entrez PY - 2010/5/29/pubmed PY - 2011/2/17/medline SP - 569 EP - 73 JF - Current opinion in clinical nutrition and metabolic care JO - Curr Opin Clin Nutr Metab Care VL - 13 IS - 5 N2 - PURPOSE OF REVIEW: Inflammatory bowel disease (IBD) is a debilitating and widespread immune-mediated illness of unknown etiology. Current treatments are modestly successful and with significant side-effects. The purpose of this review is to summarize the current understanding of mechanisms of action underlying the anti-inflammatory actions of conjugated linoleic acid (CLA) and n-3 polyunsaturated fatty acids (PUFAs) in IBD. RECENT FINDINGS: Nutrition-based interventions that target peroxisome proliferator-activated receptors (PPARs) such as dietary CLA and n-3 PUFA have demonstrated anti-inflammatory efficacy in animal models of IBD. Clinical data on n-3 PUFA in IBD remains generally unimpressive, although results of a recent human study demonstrate that IBD remission can be maintained by maintaining the n-3: n-6 ratio more than 0.65 via n-3 PUFA intervention. In mice, CLA prevented inflammation-driven colorectal cancer by activating PPAR gamma and modulating regulatory T cells and macrophages. CLA is the subject of an ongoing clinical study in Crohn's disease patients. SUMMARY: Compelling evidence demonstrates that n-3 PUFA and CLA prevent or ameliorate IBD in animal models. However, this basic knowledge has not been translated into novel nutrition-based clinical interventions. For both compounds there is an urgent need for placebo-controlled, large-scale, multicenter clinical trials. SN - 1473-6519 UR - https://www.unboundmedicine.com/medline/citation/20508519/Dietary_conjugated_linoleic_acid_and_n_3_polyunsaturated_fatty_acids_in_inflammatory_bowel_disease_ L2 - http://Insights.ovid.com/pubmed?pmid=20508519 DB - PRIME DP - Unbound Medicine ER -